These reagents are used to help introduce genetic material into cells and play a key role in the production of viral vectors for cell and gene therapies.

The transaction is expected to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions.

“This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future. As a leader in the production of viral vectors, our goal is to make the significant potential of cell and gene therapy available for patients worldwide,” said Belén Garijo, CEO of Merck.

“Novel modalities, such as viral vector-based cell and gene therapies, hold immense promise to improve the lives of patients. Combining Mirus Bio's leading technology with Merck's bioprocessing expertise and portfolio allows us to provide solutions for almost every step of viral vector development and manufacturing,” commented Matthias Heinzel, CEO of Merck’s Life Science division. “With our integrated offering along the viral vector value chain, we are now well-positioned to support our customers in this fast-growing market to positively impact the lives and health of patients worldwide,” Heinzel added.

Dale Gordon, CEO of Mirus Bio said: “We have been driving innovation in nucleic acid delivery for two decades. Merck’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”

The transaction with Gamma Biosciences, a life sciences platform established by global investment firm KKR, for the acquisition of Mirus Bio is expected to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions.